Search Login Register

Sjogren-Larsson Syndrome Summary

Description: An autosomal recessive neurocutaneous disorder characterized by severe ichthyosis MENTAL RETARDATION; SPASTIC PARAPLEGIA; and congenital ICHTHYOSIS. It is caused by mutation of gene encoding microsomal fatty ALDEHYDE DEHYDROGENASE leading to defect in fatty alcohol metabolism.

Also Known As: FALDH Deficiency; Fatty Alcohol:NAD+ Oxidoreductase Deficiency; Fatty Aldehyde Dehydrogenase Deficiency; Fatty Aldehyde Dehydrogenase Deficiency Disease; Ichthyosis, Spastic Neurologic Disorder, and Oligophrenia Show All >>

Networked: 12 relevant articles (0 outcomes, 0 trials/studies) for this Disease

Key Drugs and Agents for Sjogren-Larsson Syndrome

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. long-chain-aldehyde dehydrogenase : 6 results : IBA
  2. Pyridoxine (Pyridoxin) : 1 result : FDA 27 Generic
  3. NAD (NADH) : 1 result : IBA
  4. Unsaturated Fatty Acids (Polyunsaturated Fatty Acids) : 1 result : IBA
  5. Aldehydes : 1 result : IBA
  6. Aldehyde Dehydrogenase : 1 result : IBA
  7. Alcohols : 1 result : IBA
  8. Hyperprolinemia : 1 result : IBA
  9. Histidinemia : 1 result : IBA
  10. Rud Syndrome : 1 result : IBA
Show All >>

Diseases Related to Sjogren-Larsson Syndrome

  1. Muscle Spasticity (Spastic)
  2. Neurocutaneous Syndromes (Phakomatoses)
  3. Seizures (Seizure)
  4. Quadriplegia (Locked In Syndrome)
  5. Paresis (Hemiparesis)
Show All >>

Key Therapies for Sjogren-Larsson Syndrome

Efficacy Chart >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.